Biovectra inc. private company information – bloomberg gum abscess after tooth extraction

BioVectra Inc., a contract development and manufacturing company, manufactures and supplies ingredients for pharmaceutical and biotechnology clients in the North American and European markets. It offers clinical diagnostic raw materials, high molecular weight Vectra mPEG derivatives, and neurochemicals, as well as reducing, bio processing, and molecular biology reagents. The company’s products are used in the treatment of cancer, kidney disease, cardiovascular disease, multiple sclerosis, and other serious diseases. In addition, it provides contract manufacturing services, such as microbial/fungal fermentation, complex chemical manufacturing, biomass extraction and purification, M-Polyethyle…

BioVectra Inc., a contract development and manufacturing company, manufactures and supplies ingredients for pharmaceutical and biotechnology clients in the North American and European markets.


It offers clinical diagnostic raw materials, high molecular weight Vectra mPEG derivatives, and neurochemicals, as well as reducing, bio processing, and molecular biology reagents. The company’s products are used in the treatment of cancer, kidney disease, cardiovascular disease, multiple sclerosis, and other serious diseases. In addition, it provides contract manufacturing services, such as microbial/fungal fermentation, complex chemical manufacturing, biomass extraction and purification, M-Polyethylene glycol functionalization, and high potency chemical processing. The company offers its products through distributors in the United States, the United Kingdom, Ireland, Austria, Switzerland, Japan, Australia, France, Italy, and Israel. BioVectra Inc. was formerly known as Diagnostic Chemicals Limited and changed its name to BioVectra Inc. in December 2007. The company was founded in 1970 and is based in Charlottetown, Canada. As of January 18, 2013, BioVectra Inc. operates as a subsidiary of Mallinckrodt Public Limited Company.

On December 11, 2017, Keryx Biopharmaceuticals, Inc. and BioVectra Inc. entered into a Product Manufacture and Supply and Facility Construction Agreement for BioVectra’s construction of a manufacturing facility in Charlottetown, Prince Edward Island, Canada, expanding the site of their current facility, and BioVectra’s manufacture and supply of GMP-grade quantities of the proprietary active pharmaceutical ingredient for Keryx’s drug product, Auryxia. Pursuant to the agreement, Keryx has agreed to order a minimum quantity of product annually and will be invoiced for the difference if the purchased quantity is lower than the minimum quantity. BioVectra has committed to achieve timely delivery of product and to supply Keryx’s annual ordered quantities of product up to the facility’s working capacity. After a specified time, BioVectra will issue a credit to Keryx if it has failed to deliver a minimum percentage of the quantity of product ordered by Keryx, measured on both a quarterly and an annual basis. The agreement has an initial term ending on the later of December 31, 2026 or a specified time from the commencement of the commercial supply term and will automatically renew after the initial term for successive terms of one year each, unless either party gives notice of its intention to terminate the agreement within a specified time prior to the end of the then current term.